文献速递胸部肿瘤放疗放疗物理与技术

III期非小细胞肺癌同步放化疗后放射性肺炎的时空剂量分布

Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients.
PubMed 文献 · Radiat Oncol · 2017-11-02

结果显示,从临床诊断到最大范围,放射性肺炎体积内相对剂量体积比例从≤20 Gy区域向>40 Gy区域显著转移,提示减少健康肺组织V40可能作为放疗计划的额外参数。

要点

  • 放射性肺炎从确诊到最大范围,剂量分布由低剂量区向高剂量区转移。
  • ≤20 Gy相对剂量体积比例从30.2%降至21.9%(p=0.04)。
  • >40 Gy相对剂量体积比例从39.2%升至49.8%(p=0.02)。

核心结论

  • 放射性肺炎从确诊到最大范围,其体积内相对剂量比例从≤20 Gy低剂量区显著向>40 Gy高剂量区转移。

主要发现

  • 放射性肺炎确诊时主要分布于肺低剂量区,最大范围时主要分布于高剂量区,相对平均剂量体积比例发生显著转移。
  • ≤20 Gy相对剂量体积比例从30.2%(范围0-100)降至21.9%(范围0-100),p=0.04。
  • >40 Gy相对剂量体积比例从39.2%(范围0-100)升至49.8%(范围0-100),p=0.02。
  • >20至≤40 Gy相对剂量体积比例从30.6%(范围0-85.7)略降至28.3%(范围0-85.7),p=0.34。

临床怎么用

  • 减少健康肺组织接受>40 Gy的体积(V40)可能作为肺癌放疗计划的额外参数。

局限性

  • 放射性肺炎体积内剂量比例变化的临床影响尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Radiation pneumonitis (RP) is the most common subacute side effect after concurrent chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer. Several clinical and dose-volume (DV) parameters are associated with a distinct risk of symptomatic RP. The aim of this study was to assess the spatial dose distribution of the RP volume from first occurence to maximum volume expansion of RP. MATERIAL AND METHODS: Between 2007 and 2015, 732 patients with lung cancer were treated in an institution. Thirty-three patients met the following inclusion criteria: an RP grade II after CRT and a radiation dose ≥60 Gy and no prior medical history of cardiopulmonary comorbidities. The images of the first chest computed tomography (CT) confirming the diagnosis of RP and the CT images showing the maximum expansion of RP were merged with the treatment plan. The RP volume was delineated within the treatment plan, and a DV analysis was performed to evaluate the lung dose volume areas in which the RP manifested over time and whether dose volume changes within the RP volume occurred. RESULTS: A change from clinical diagnosis to maximum expansion of RP was observed as the RP at clinical appearance mainly manifested in the lower dose areas of the lung, whereas the RP volume at maximum expansion manifested in the higher dose areas, resulting in a significant shift of the assessed relative mean dose volume proportions within the RP volume. The mean relative dose volume proportion 0- ≤ 20 Gy decreased from 30.2% (range, 0-100) to 21.9% (range, 0-100; p = 0.04) at the expense of the dose volume > 40 Gy which increased from 39.2% (range, 0-100) to 49.8% (range, 0-100; p = 0.02), whereas the dose relative volume proportion > 20- ≤ 40 Gy showed no relevant change and slightly decreased from 30.6% (range, 0-85.7) to 28.3%, (range, 0-85.7; p = 0.34). CONCLUSION: We observed a considerable increase in the relative dose proportions within the RP volume from diagnosis to maximum volume extent from low dose zones below 20 Gy to zones above 40 Gy. Although the clinical impact on RP remains unknown, a reduction of healthy healthy lung tissue receiving >40 Gy (V40) might be an additional parameter for irradiation planning in lung cancer patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Alharbi M, Janssen S, Golpon H, et al. Temporal and spatial dose distribution of radiation pneumonitis after concurrent radiochemotherapy in stage III non-small cell cancer patients. Radiat Oncol. 2017. PMID: 29096667. doi:10.1186/s13014-017-0898-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。